The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Should we act therapeutically on MRD positivity in AML?
Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
